Insider Buying: Palisade Bio (NASDAQ:PALI) Director Acquires $41,000.00 in Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 20,000 shares of the stock in a transaction dated Monday, July 6th. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $41,000.00. Following the completion of the transaction, the director owned 386,904 shares of the company’s stock, valued at $793,153.20. The trade was a 5.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 9th, Robert Jr. Baltera acquired 25,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.96 per share, with a total value of $49,000.00.
• On Wednesday, July 8th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $1.99 per share, with a total value of $39,800.00.
• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $2.03 per share, with a total value of $60,900.00.
• On Thursday, July 2nd, Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The stock was bought at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Stock Down 0.5%

Shares of PALI stock opened at $1.96 on Friday. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.85. The firm has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.92. The company has a market capitalization of $340.22 million, a P/E ratio of -1.94 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, research analysts expect that Palisade Bio, Inc. will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Palisade Bio

A number of institutional investors have recently modified their holdings of the business. Cetera Investment Advisers acquired a new position in Palisade Bio in the 4th quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Palisade Bio in the 4th quarter valued at $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio in the 4th quarter valued at $28,000. Atom Investors LP bought a new stake in shares of Palisade Bio during the 4th quarter worth $33,000. Finally, Barclays PLC acquired a new stake in Palisade Bio in the fourth quarter valued at about $35,000. Institutional investors own 11.79% of the company’s stock.

Wall Street Analysts Forecast Growth

PALI has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Oppenheimer set a $7.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Finally, Wolfe Research started coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.